Singapore markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
65.42+0.15 (+0.23%)
At close: 04:00PM EDT
65.50 +0.08 (+0.12%)
After hours: 07:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close65.27
Open65.50
Bid65.37 x 800
Ask65.50 x 800
Day's range64.64 - 66.35
52-week range64.63 - 87.87
Volume12,348,617
Avg. volume7,428,992
Market cap81.577B
Beta (5Y monthly)N/A
PE ratio (TTM)14.54
EPS (TTM)4.50
Earnings date25 Apr 2024
Forward dividend & yield3.08 (4.72%)
Ex-dividend date14 Mar 2024
1y target est83.88
  • Zacks

    Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat

    Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.

  • Thomson Reuters StreetEvents

    Q1 2024 Gilead Sciences Inc Earnings Call

    Q1 2024 Gilead Sciences Inc Earnings Call

  • Business Wire

    FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV

    FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of